Global Circulating Tumor DNA Diagnostics Market 2024 by Company, Regions, Type and Application, Forecast to 2030

Page: 84

Published Date: 26 Jan 2024

Category: Medical Care

PDF Download

Get FREE Sample

Customize Request

Description
Table of Contents
Table of Figures
Research Methodology
Companies Mentioned
Related Reports
Product Tags

Description

According to our (Global Info Research) latest study, the global Circulating Tumor DNA Diagnostics market size was valued at USD 13180 million in 2023 and is forecast to a readjusted size of USD 18990 million by 2030 with a CAGR of 5.4% during review period.

Circulating tumor DNA (ctDNA) diagnostics, also known as liquid biopsy, is a non-invasive method for detecting and analyzing genetic alterations associated with cancer. This approach involves the identification of DNA fragments released by cancer cells into the bloodstream. These fragments, known as circulating tumor DNA, carry genetic information that can provide insights into the presence, characteristics, and progression of cancer.

The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.

The Global Info Research report includes an overview of the development of the Circulating Tumor DNA Diagnostics industry chain, the market status of Hospitals (Test Kits, Reagents), Diagnostics Laboratories (Test Kits, Reagents), and key enterprises in developed and developing market, and analysed the cutting-edge technology, patent, hot applications and market trends of Circulating Tumor DNA Diagnostics.

Regionally, the report analyzes the Circulating Tumor DNA Diagnostics markets in key regions. North America and Europe are experiencing steady growth, driven by government initiatives and increasing consumer awareness. Asia-Pacific, particularly China, leads the global Circulating Tumor DNA Diagnostics market, with robust domestic demand, supportive policies, and a strong manufacturing base.

Key Features:
The report presents comprehensive understanding of the Circulating Tumor DNA Diagnostics market. It provides a holistic view of the industry, as well as detailed insights into individual components and stakeholders. The report analysis market dynamics, trends, challenges, and opportunities within the Circulating Tumor DNA Diagnostics industry.

The report involves analyzing the market at a macro level:
Market Sizing and Segmentation: Report collect data on the overall market size, including the revenue generated, and market share of different by Type (e.g., Test Kits, Reagents).

Industry Analysis: Report analyse the broader industry trends, such as government policies and regulations, technological advancements, consumer preferences, and market dynamics. This analysis helps in understanding the key drivers and challenges influencing the Circulating Tumor DNA Diagnostics market.

Regional Analysis: The report involves examining the Circulating Tumor DNA Diagnostics market at a regional or national level. Report analyses regional factors such as government incentives, infrastructure development, economic conditions, and consumer behaviour to identify variations and opportunities within different markets.

Market Projections: Report covers the gathered data and analysis to make future projections and forecasts for the Circulating Tumor DNA Diagnostics market. This may include estimating market growth rates, predicting market demand, and identifying emerging trends.

The report also involves a more granular approach to Circulating Tumor DNA Diagnostics:
Company Analysis: Report covers individual Circulating Tumor DNA Diagnostics players, suppliers, and other relevant industry players. This analysis includes studying their financial performance, market positioning, product portfolios, partnerships, and strategies.

Consumer Analysis: Report covers data on consumer behaviour, preferences, and attitudes towards Circulating Tumor DNA Diagnostics This may involve surveys, interviews, and analysis of consumer reviews and feedback from different by Application (Hospitals, Diagnostics Laboratories).

Technology Analysis: Report covers specific technologies relevant to Circulating Tumor DNA Diagnostics. It assesses the current state, advancements, and potential future developments in Circulating Tumor DNA Diagnostics areas.

Competitive Landscape: By analyzing individual companies, suppliers, and consumers, the report present insights into the competitive landscape of the Circulating Tumor DNA Diagnostics market. This analysis helps understand market share, competitive advantages, and potential areas for differentiation among industry players.

Market Validation: The report involves validating findings and projections through primary research, such as surveys, interviews, and focus groups.

Market Segmentation
Circulating Tumor DNA Diagnostics market is split by Type and by Application. For the period 2019-2030, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of value.

Market segment by Type
Test Kits
Reagents

Market segment by Application
Hospitals
Diagnostics Laboratories
Research Laboratories
Academic Research Institutes

Market segment by players, this report covers
Grail, Inc.
Guardant Health, Inc.
Biodesix, Inc.
Exosome Diagnostics
Freenome Inc.
LungLife AI, Inc.
Inivata Ltd.
Personal Genome Diagnostics, Inc.
CellMax Life

Market segment by regions, regional analysis covers
North America (United States, Canada, and Mexico)
Europe (Germany, France, UK, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Australia and Rest of Asia-Pacific)
South America (Brazil, Argentina and Rest of South America)
Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)

The content of the study subjects, includes a total of 13 chapters:
Chapter 1, to describe Circulating Tumor DNA Diagnostics product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top players of Circulating Tumor DNA Diagnostics, with revenue, gross margin and global market share of Circulating Tumor DNA Diagnostics from 2019 to 2024.
Chapter 3, the Circulating Tumor DNA Diagnostics competitive situation, revenue and global market share of top players are analyzed emphatically by landscape contrast.
Chapter 4 and 5, to segment the market size by Type and application, with consumption value and growth rate by Type, application, from 2019 to 2030.
Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2019 to 2024.and Circulating Tumor DNA Diagnostics market forecast, by regions, type and application, with consumption value, from 2025 to 2030.
Chapter 11, market dynamics, drivers, restraints, trends and Porters Five Forces analysis.
Chapter 12, the key raw materials and key suppliers, and industry chain of Circulating Tumor DNA Diagnostics.
Chapter 13, to describe Circulating Tumor DNA Diagnostics research findings and conclusion.

Table of Contents

1 Market Overview
    1.1 Product Overview and Scope of Circulating Tumor DNA Diagnostics
    1.2 Market Estimation Caveats and Base Year
    1.3 Classification of Circulating Tumor DNA Diagnostics by Type
        1.3.1 Overview: Global Circulating Tumor DNA Diagnostics Market Size by Type: 2019 Versus 2023 Versus 2030
        1.3.2 Global Circulating Tumor DNA Diagnostics Consumption Value Market Share by Type in 2023
        1.3.3 Test Kits
        1.3.4 Reagents
    1.4 Global Circulating Tumor DNA Diagnostics Market by Application
        1.4.1 Overview: Global Circulating Tumor DNA Diagnostics Market Size by Application: 2019 Versus 2023 Versus 2030
        1.4.2 Hospitals
        1.4.3 Diagnostics Laboratories
        1.4.4 Research Laboratories
        1.4.5 Academic Research Institutes
    1.5 Global Circulating Tumor DNA Diagnostics Market Size & Forecast
    1.6 Global Circulating Tumor DNA Diagnostics Market Size and Forecast by Region
        1.6.1 Global Circulating Tumor DNA Diagnostics Market Size by Region: 2019 VS 2023 VS 2030
        1.6.2 Global Circulating Tumor DNA Diagnostics Market Size by Region, (2019-2030)
        1.6.3 North America Circulating Tumor DNA Diagnostics Market Size and Prospect (2019-2030)
        1.6.4 Europe Circulating Tumor DNA Diagnostics Market Size and Prospect (2019-2030)
        1.6.5 Asia-Pacific Circulating Tumor DNA Diagnostics Market Size and Prospect (2019-2030)
        1.6.6 South America Circulating Tumor DNA Diagnostics Market Size and Prospect (2019-2030)
        1.6.7 Middle East and Africa Circulating Tumor DNA Diagnostics Market Size and Prospect (2019-2030)

2 Company Profiles
    2.1 Grail, Inc.
        2.1.1 Grail, Inc. Details
        2.1.2 Grail, Inc. Major Business
        2.1.3 Grail, Inc. Circulating Tumor DNA Diagnostics Product and Solutions
        2.1.4 Grail, Inc. Circulating Tumor DNA Diagnostics Revenue, Gross Margin and Market Share (2019-2024)
        2.1.5 Grail, Inc. Recent Developments and Future Plans
    2.2 Guardant Health, Inc.
        2.2.1 Guardant Health, Inc. Details
        2.2.2 Guardant Health, Inc. Major Business
        2.2.3 Guardant Health, Inc. Circulating Tumor DNA Diagnostics Product and Solutions
        2.2.4 Guardant Health, Inc. Circulating Tumor DNA Diagnostics Revenue, Gross Margin and Market Share (2019-2024)
        2.2.5 Guardant Health, Inc. Recent Developments and Future Plans
    2.3 Biodesix, Inc.
        2.3.1 Biodesix, Inc. Details
        2.3.2 Biodesix, Inc. Major Business
        2.3.3 Biodesix, Inc. Circulating Tumor DNA Diagnostics Product and Solutions
        2.3.4 Biodesix, Inc. Circulating Tumor DNA Diagnostics Revenue, Gross Margin and Market Share (2019-2024)
        2.3.5 Biodesix, Inc. Recent Developments and Future Plans
    2.4 Exosome Diagnostics
        2.4.1 Exosome Diagnostics Details
        2.4.2 Exosome Diagnostics Major Business
        2.4.3 Exosome Diagnostics Circulating Tumor DNA Diagnostics Product and Solutions
        2.4.4 Exosome Diagnostics Circulating Tumor DNA Diagnostics Revenue, Gross Margin and Market Share (2019-2024)
        2.4.5 Exosome Diagnostics Recent Developments and Future Plans
    2.5 Freenome Inc.
        2.5.1 Freenome Inc. Details
        2.5.2 Freenome Inc. Major Business
        2.5.3 Freenome Inc. Circulating Tumor DNA Diagnostics Product and Solutions
        2.5.4 Freenome Inc. Circulating Tumor DNA Diagnostics Revenue, Gross Margin and Market Share (2019-2024)
        2.5.5 Freenome Inc. Recent Developments and Future Plans
    2.6 LungLife AI, Inc.
        2.6.1 LungLife AI, Inc. Details
        2.6.2 LungLife AI, Inc. Major Business
        2.6.3 LungLife AI, Inc. Circulating Tumor DNA Diagnostics Product and Solutions
        2.6.4 LungLife AI, Inc. Circulating Tumor DNA Diagnostics Revenue, Gross Margin and Market Share (2019-2024)
        2.6.5 LungLife AI, Inc. Recent Developments and Future Plans
    2.7 Inivata Ltd.
        2.7.1 Inivata Ltd. Details
        2.7.2 Inivata Ltd. Major Business
        2.7.3 Inivata Ltd. Circulating Tumor DNA Diagnostics Product and Solutions
        2.7.4 Inivata Ltd. Circulating Tumor DNA Diagnostics Revenue, Gross Margin and Market Share (2019-2024)
        2.7.5 Inivata Ltd. Recent Developments and Future Plans
    2.8 Personal Genome Diagnostics, Inc.
        2.8.1 Personal Genome Diagnostics, Inc. Details
        2.8.2 Personal Genome Diagnostics, Inc. Major Business
        2.8.3 Personal Genome Diagnostics, Inc. Circulating Tumor DNA Diagnostics Product and Solutions
        2.8.4 Personal Genome Diagnostics, Inc. Circulating Tumor DNA Diagnostics Revenue, Gross Margin and Market Share (2019-2024)
        2.8.5 Personal Genome Diagnostics, Inc. Recent Developments and Future Plans
    2.9 CellMax Life
        2.9.1 CellMax Life Details
        2.9.2 CellMax Life Major Business
        2.9.3 CellMax Life Circulating Tumor DNA Diagnostics Product and Solutions
        2.9.4 CellMax Life Circulating Tumor DNA Diagnostics Revenue, Gross Margin and Market Share (2019-2024)
        2.9.5 CellMax Life Recent Developments and Future Plans

3 Market Competition, by Players
    3.1 Global Circulating Tumor DNA Diagnostics Revenue and Share by Players (2019-2024)
    3.2 Market Share Analysis (2023)
        3.2.1 Market Share of Circulating Tumor DNA Diagnostics by Company Revenue
        3.2.2 Top 3 Circulating Tumor DNA Diagnostics Players Market Share in 2023
        3.2.3 Top 6 Circulating Tumor DNA Diagnostics Players Market Share in 2023
    3.3 Circulating Tumor DNA Diagnostics Market: Overall Company Footprint Analysis
        3.3.1 Circulating Tumor DNA Diagnostics Market: Region Footprint
        3.3.2 Circulating Tumor DNA Diagnostics Market: Company Product Type Footprint
        3.3.3 Circulating Tumor DNA Diagnostics Market: Company Product Application Footprint
    3.4 New Market Entrants and Barriers to Market Entry
    3.5 Mergers, Acquisition, Agreements, and Collaborations

4 Market Size Segment by Type
    4.1 Global Circulating Tumor DNA Diagnostics Consumption Value and Market Share by Type (2019-2024)
    4.2 Global Circulating Tumor DNA Diagnostics Market Forecast by Type (2025-2030)

5 Market Size Segment by Application
    5.1 Global Circulating Tumor DNA Diagnostics Consumption Value Market Share by Application (2019-2024)
    5.2 Global Circulating Tumor DNA Diagnostics Market Forecast by Application (2025-2030)

6 North America
    6.1 North America Circulating Tumor DNA Diagnostics Consumption Value by Type (2019-2030)
    6.2 North America Circulating Tumor DNA Diagnostics Consumption Value by Application (2019-2030)
    6.3 North America Circulating Tumor DNA Diagnostics Market Size by Country
        6.3.1 North America Circulating Tumor DNA Diagnostics Consumption Value by Country (2019-2030)
        6.3.2 United States Circulating Tumor DNA Diagnostics Market Size and Forecast (2019-2030)
        6.3.3 Canada Circulating Tumor DNA Diagnostics Market Size and Forecast (2019-2030)
        6.3.4 Mexico Circulating Tumor DNA Diagnostics Market Size and Forecast (2019-2030)

7 Europe
    7.1 Europe Circulating Tumor DNA Diagnostics Consumption Value by Type (2019-2030)
    7.2 Europe Circulating Tumor DNA Diagnostics Consumption Value by Application (2019-2030)
    7.3 Europe Circulating Tumor DNA Diagnostics Market Size by Country
        7.3.1 Europe Circulating Tumor DNA Diagnostics Consumption Value by Country (2019-2030)
        7.3.2 Germany Circulating Tumor DNA Diagnostics Market Size and Forecast (2019-2030)
        7.3.3 France Circulating Tumor DNA Diagnostics Market Size and Forecast (2019-2030)
        7.3.4 United Kingdom Circulating Tumor DNA Diagnostics Market Size and Forecast (2019-2030)
        7.3.5 Russia Circulating Tumor DNA Diagnostics Market Size and Forecast (2019-2030)
        7.3.6 Italy Circulating Tumor DNA Diagnostics Market Size and Forecast (2019-2030)

8 Asia-Pacific
    8.1 Asia-Pacific Circulating Tumor DNA Diagnostics Consumption Value by Type (2019-2030)
    8.2 Asia-Pacific Circulating Tumor DNA Diagnostics Consumption Value by Application (2019-2030)
    8.3 Asia-Pacific Circulating Tumor DNA Diagnostics Market Size by Region
        8.3.1 Asia-Pacific Circulating Tumor DNA Diagnostics Consumption Value by Region (2019-2030)
        8.3.2 China Circulating Tumor DNA Diagnostics Market Size and Forecast (2019-2030)
        8.3.3 Japan Circulating Tumor DNA Diagnostics Market Size and Forecast (2019-2030)
        8.3.4 South Korea Circulating Tumor DNA Diagnostics Market Size and Forecast (2019-2030)
        8.3.5 India Circulating Tumor DNA Diagnostics Market Size and Forecast (2019-2030)
        8.3.6 Southeast Asia Circulating Tumor DNA Diagnostics Market Size and Forecast (2019-2030)
        8.3.7 Australia Circulating Tumor DNA Diagnostics Market Size and Forecast (2019-2030)

9 South America
    9.1 South America Circulating Tumor DNA Diagnostics Consumption Value by Type (2019-2030)
    9.2 South America Circulating Tumor DNA Diagnostics Consumption Value by Application (2019-2030)
    9.3 South America Circulating Tumor DNA Diagnostics Market Size by Country
        9.3.1 South America Circulating Tumor DNA Diagnostics Consumption Value by Country (2019-2030)
        9.3.2 Brazil Circulating Tumor DNA Diagnostics Market Size and Forecast (2019-2030)
        9.3.3 Argentina Circulating Tumor DNA Diagnostics Market Size and Forecast (2019-2030)

10 Middle East & Africa
    10.1 Middle East & Africa Circulating Tumor DNA Diagnostics Consumption Value by Type (2019-2030)
    10.2 Middle East & Africa Circulating Tumor DNA Diagnostics Consumption Value by Application (2019-2030)
    10.3 Middle East & Africa Circulating Tumor DNA Diagnostics Market Size by Country
        10.3.1 Middle East & Africa Circulating Tumor DNA Diagnostics Consumption Value by Country (2019-2030)
        10.3.2 Turkey Circulating Tumor DNA Diagnostics Market Size and Forecast (2019-2030)
        10.3.3 Saudi Arabia Circulating Tumor DNA Diagnostics Market Size and Forecast (2019-2030)
        10.3.4 UAE Circulating Tumor DNA Diagnostics Market Size and Forecast (2019-2030)

11 Market Dynamics
    11.1 Circulating Tumor DNA Diagnostics Market Drivers
    11.2 Circulating Tumor DNA Diagnostics Market Restraints
    11.3 Circulating Tumor DNA Diagnostics Trends Analysis
    11.4 Porters Five Forces Analysis
        11.4.1 Threat of New Entrants
        11.4.2 Bargaining Power of Suppliers
        11.4.3 Bargaining Power of Buyers
        11.4.4 Threat of Substitutes
        11.4.5 Competitive Rivalry

12 Industry Chain Analysis
    12.1 Circulating Tumor DNA Diagnostics Industry Chain
    12.2 Circulating Tumor DNA Diagnostics Upstream Analysis
    12.3 Circulating Tumor DNA Diagnostics Midstream Analysis
    12.4 Circulating Tumor DNA Diagnostics Downstream Analysis

13 Research Findings and Conclusion

14 Appendix
    14.1 Methodology
    14.2 Research Process and Data Source
    14.3 Disclaimer

Table of Figures

List of Tables
    Table 1. Global Circulating Tumor DNA Diagnostics Consumption Value by Type, (USD Million), 2019 & 2023 & 2030
    Table 2. Global Circulating Tumor DNA Diagnostics Consumption Value by Application, (USD Million), 2019 & 2023 & 2030
    Table 3. Global Circulating Tumor DNA Diagnostics Consumption Value by Region (2019-2024) & (USD Million)
    Table 4. Global Circulating Tumor DNA Diagnostics Consumption Value by Region (2025-2030) & (USD Million)
    Table 5. Grail, Inc. Company Information, Head Office, and Major Competitors
    Table 6. Grail, Inc. Major Business
    Table 7. Grail, Inc. Circulating Tumor DNA Diagnostics Product and Solutions
    Table 8. Grail, Inc. Circulating Tumor DNA Diagnostics Revenue (USD Million), Gross Margin and Market Share (2019-2024)
    Table 9. Grail, Inc. Recent Developments and Future Plans
    Table 10. Guardant Health, Inc. Company Information, Head Office, and Major Competitors
    Table 11. Guardant Health, Inc. Major Business
    Table 12. Guardant Health, Inc. Circulating Tumor DNA Diagnostics Product and Solutions
    Table 13. Guardant Health, Inc. Circulating Tumor DNA Diagnostics Revenue (USD Million), Gross Margin and Market Share (2019-2024)
    Table 14. Guardant Health, Inc. Recent Developments and Future Plans
    Table 15. Biodesix, Inc. Company Information, Head Office, and Major Competitors
    Table 16. Biodesix, Inc. Major Business
    Table 17. Biodesix, Inc. Circulating Tumor DNA Diagnostics Product and Solutions
    Table 18. Biodesix, Inc. Circulating Tumor DNA Diagnostics Revenue (USD Million), Gross Margin and Market Share (2019-2024)
    Table 19. Biodesix, Inc. Recent Developments and Future Plans
    Table 20. Exosome Diagnostics Company Information, Head Office, and Major Competitors
    Table 21. Exosome Diagnostics Major Business
    Table 22. Exosome Diagnostics Circulating Tumor DNA Diagnostics Product and Solutions
    Table 23. Exosome Diagnostics Circulating Tumor DNA Diagnostics Revenue (USD Million), Gross Margin and Market Share (2019-2024)
    Table 24. Exosome Diagnostics Recent Developments and Future Plans
    Table 25. Freenome Inc. Company Information, Head Office, and Major Competitors
    Table 26. Freenome Inc. Major Business
    Table 27. Freenome Inc. Circulating Tumor DNA Diagnostics Product and Solutions
    Table 28. Freenome Inc. Circulating Tumor DNA Diagnostics Revenue (USD Million), Gross Margin and Market Share (2019-2024)
    Table 29. Freenome Inc. Recent Developments and Future Plans
    Table 30. LungLife AI, Inc. Company Information, Head Office, and Major Competitors
    Table 31. LungLife AI, Inc. Major Business
    Table 32. LungLife AI, Inc. Circulating Tumor DNA Diagnostics Product and Solutions
    Table 33. LungLife AI, Inc. Circulating Tumor DNA Diagnostics Revenue (USD Million), Gross Margin and Market Share (2019-2024)
    Table 34. LungLife AI, Inc. Recent Developments and Future Plans
    Table 35. Inivata Ltd. Company Information, Head Office, and Major Competitors
    Table 36. Inivata Ltd. Major Business
    Table 37. Inivata Ltd. Circulating Tumor DNA Diagnostics Product and Solutions
    Table 38. Inivata Ltd. Circulating Tumor DNA Diagnostics Revenue (USD Million), Gross Margin and Market Share (2019-2024)
    Table 39. Inivata Ltd. Recent Developments and Future Plans
    Table 40. Personal Genome Diagnostics, Inc. Company Information, Head Office, and Major Competitors
    Table 41. Personal Genome Diagnostics, Inc. Major Business
    Table 42. Personal Genome Diagnostics, Inc. Circulating Tumor DNA Diagnostics Product and Solutions
    Table 43. Personal Genome Diagnostics, Inc. Circulating Tumor DNA Diagnostics Revenue (USD Million), Gross Margin and Market Share (2019-2024)
    Table 44. Personal Genome Diagnostics, Inc. Recent Developments and Future Plans
    Table 45. CellMax Life Company Information, Head Office, and Major Competitors
    Table 46. CellMax Life Major Business
    Table 47. CellMax Life Circulating Tumor DNA Diagnostics Product and Solutions
    Table 48. CellMax Life Circulating Tumor DNA Diagnostics Revenue (USD Million), Gross Margin and Market Share (2019-2024)
    Table 49. CellMax Life Recent Developments and Future Plans
    Table 50. Global Circulating Tumor DNA Diagnostics Revenue (USD Million) by Players (2019-2024)
    Table 51. Global Circulating Tumor DNA Diagnostics Revenue Share by Players (2019-2024)
    Table 52. Breakdown of Circulating Tumor DNA Diagnostics by Company Type (Tier 1, Tier 2, and Tier 3)
    Table 53. Market Position of Players in Circulating Tumor DNA Diagnostics, (Tier 1, Tier 2, and Tier 3), Based on Revenue in 2023
    Table 54. Head Office of Key Circulating Tumor DNA Diagnostics Players
    Table 55. Circulating Tumor DNA Diagnostics Market: Company Product Type Footprint
    Table 56. Circulating Tumor DNA Diagnostics Market: Company Product Application Footprint
    Table 57. Circulating Tumor DNA Diagnostics New Market Entrants and Barriers to Market Entry
    Table 58. Circulating Tumor DNA Diagnostics Mergers, Acquisition, Agreements, and Collaborations
    Table 59. Global Circulating Tumor DNA Diagnostics Consumption Value (USD Million) by Type (2019-2024)
    Table 60. Global Circulating Tumor DNA Diagnostics Consumption Value Share by Type (2019-2024)
    Table 61. Global Circulating Tumor DNA Diagnostics Consumption Value Forecast by Type (2025-2030)
    Table 62. Global Circulating Tumor DNA Diagnostics Consumption Value by Application (2019-2024)
    Table 63. Global Circulating Tumor DNA Diagnostics Consumption Value Forecast by Application (2025-2030)
    Table 64. North America Circulating Tumor DNA Diagnostics Consumption Value by Type (2019-2024) & (USD Million)
    Table 65. North America Circulating Tumor DNA Diagnostics Consumption Value by Type (2025-2030) & (USD Million)
    Table 66. North America Circulating Tumor DNA Diagnostics Consumption Value by Application (2019-2024) & (USD Million)
    Table 67. North America Circulating Tumor DNA Diagnostics Consumption Value by Application (2025-2030) & (USD Million)
    Table 68. North America Circulating Tumor DNA Diagnostics Consumption Value by Country (2019-2024) & (USD Million)
    Table 69. North America Circulating Tumor DNA Diagnostics Consumption Value by Country (2025-2030) & (USD Million)
    Table 70. Europe Circulating Tumor DNA Diagnostics Consumption Value by Type (2019-2024) & (USD Million)
    Table 71. Europe Circulating Tumor DNA Diagnostics Consumption Value by Type (2025-2030) & (USD Million)
    Table 72. Europe Circulating Tumor DNA Diagnostics Consumption Value by Application (2019-2024) & (USD Million)
    Table 73. Europe Circulating Tumor DNA Diagnostics Consumption Value by Application (2025-2030) & (USD Million)
    Table 74. Europe Circulating Tumor DNA Diagnostics Consumption Value by Country (2019-2024) & (USD Million)
    Table 75. Europe Circulating Tumor DNA Diagnostics Consumption Value by Country (2025-2030) & (USD Million)
    Table 76. Asia-Pacific Circulating Tumor DNA Diagnostics Consumption Value by Type (2019-2024) & (USD Million)
    Table 77. Asia-Pacific Circulating Tumor DNA Diagnostics Consumption Value by Type (2025-2030) & (USD Million)
    Table 78. Asia-Pacific Circulating Tumor DNA Diagnostics Consumption Value by Application (2019-2024) & (USD Million)
    Table 79. Asia-Pacific Circulating Tumor DNA Diagnostics Consumption Value by Application (2025-2030) & (USD Million)
    Table 80. Asia-Pacific Circulating Tumor DNA Diagnostics Consumption Value by Region (2019-2024) & (USD Million)
    Table 81. Asia-Pacific Circulating Tumor DNA Diagnostics Consumption Value by Region (2025-2030) & (USD Million)
    Table 82. South America Circulating Tumor DNA Diagnostics Consumption Value by Type (2019-2024) & (USD Million)
    Table 83. South America Circulating Tumor DNA Diagnostics Consumption Value by Type (2025-2030) & (USD Million)
    Table 84. South America Circulating Tumor DNA Diagnostics Consumption Value by Application (2019-2024) & (USD Million)
    Table 85. South America Circulating Tumor DNA Diagnostics Consumption Value by Application (2025-2030) & (USD Million)
    Table 86. South America Circulating Tumor DNA Diagnostics Consumption Value by Country (2019-2024) & (USD Million)
    Table 87. South America Circulating Tumor DNA Diagnostics Consumption Value by Country (2025-2030) & (USD Million)
    Table 88. Middle East & Africa Circulating Tumor DNA Diagnostics Consumption Value by Type (2019-2024) & (USD Million)
    Table 89. Middle East & Africa Circulating Tumor DNA Diagnostics Consumption Value by Type (2025-2030) & (USD Million)
    Table 90. Middle East & Africa Circulating Tumor DNA Diagnostics Consumption Value by Application (2019-2024) & (USD Million)
    Table 91. Middle East & Africa Circulating Tumor DNA Diagnostics Consumption Value by Application (2025-2030) & (USD Million)
    Table 92. Middle East & Africa Circulating Tumor DNA Diagnostics Consumption Value by Country (2019-2024) & (USD Million)
    Table 93. Middle East & Africa Circulating Tumor DNA Diagnostics Consumption Value by Country (2025-2030) & (USD Million)
    Table 94. Circulating Tumor DNA Diagnostics Raw Material
    Table 95. Key Suppliers of Circulating Tumor DNA Diagnostics Raw Materials
List of Figures
    Figure 1. Circulating Tumor DNA Diagnostics Picture
    Figure 2. Global Circulating Tumor DNA Diagnostics Consumption Value by Type, (USD Million), 2019 & 2023 & 2030
    Figure 3. Global Circulating Tumor DNA Diagnostics Consumption Value Market Share by Type in 2023
    Figure 4. Test Kits
    Figure 5. Reagents
    Figure 6. Global Circulating Tumor DNA Diagnostics Consumption Value by Type, (USD Million), 2019 & 2023 & 2030
    Figure 7. Circulating Tumor DNA Diagnostics Consumption Value Market Share by Application in 2023
    Figure 8. Hospitals Picture
    Figure 9. Diagnostics Laboratories Picture
    Figure 10. Research Laboratories Picture
    Figure 11. Academic Research Institutes Picture
    Figure 12. Global Circulating Tumor DNA Diagnostics Consumption Value, (USD Million): 2019 & 2023 & 2030
    Figure 13. Global Circulating Tumor DNA Diagnostics Consumption Value and Forecast (2019-2030) & (USD Million)
    Figure 14. Global Market Circulating Tumor DNA Diagnostics Consumption Value (USD Million) Comparison by Region (2019 & 2023 & 2030)
    Figure 15. Global Circulating Tumor DNA Diagnostics Consumption Value Market Share by Region (2019-2030)
    Figure 16. Global Circulating Tumor DNA Diagnostics Consumption Value Market Share by Region in 2023
    Figure 17. North America Circulating Tumor DNA Diagnostics Consumption Value (2019-2030) & (USD Million)
    Figure 18. Europe Circulating Tumor DNA Diagnostics Consumption Value (2019-2030) & (USD Million)
    Figure 19. Asia-Pacific Circulating Tumor DNA Diagnostics Consumption Value (2019-2030) & (USD Million)
    Figure 20. South America Circulating Tumor DNA Diagnostics Consumption Value (2019-2030) & (USD Million)
    Figure 21. Middle East and Africa Circulating Tumor DNA Diagnostics Consumption Value (2019-2030) & (USD Million)
    Figure 22. Global Circulating Tumor DNA Diagnostics Revenue Share by Players in 2023
    Figure 23. Circulating Tumor DNA Diagnostics Market Share by Company Type (Tier 1, Tier 2 and Tier 3) in 2023
    Figure 24. Global Top 3 Players Circulating Tumor DNA Diagnostics Market Share in 2023
    Figure 25. Global Top 6 Players Circulating Tumor DNA Diagnostics Market Share in 2023
    Figure 26. Global Circulating Tumor DNA Diagnostics Consumption Value Share by Type (2019-2024)
    Figure 27. Global Circulating Tumor DNA Diagnostics Market Share Forecast by Type (2025-2030)
    Figure 28. Global Circulating Tumor DNA Diagnostics Consumption Value Share by Application (2019-2024)
    Figure 29. Global Circulating Tumor DNA Diagnostics Market Share Forecast by Application (2025-2030)
    Figure 30. North America Circulating Tumor DNA Diagnostics Consumption Value Market Share by Type (2019-2030)
    Figure 31. North America Circulating Tumor DNA Diagnostics Consumption Value Market Share by Application (2019-2030)
    Figure 32. North America Circulating Tumor DNA Diagnostics Consumption Value Market Share by Country (2019-2030)
    Figure 33. United States Circulating Tumor DNA Diagnostics Consumption Value (2019-2030) & (USD Million)
    Figure 34. Canada Circulating Tumor DNA Diagnostics Consumption Value (2019-2030) & (USD Million)
    Figure 35. Mexico Circulating Tumor DNA Diagnostics Consumption Value (2019-2030) & (USD Million)
    Figure 36. Europe Circulating Tumor DNA Diagnostics Consumption Value Market Share by Type (2019-2030)
    Figure 37. Europe Circulating Tumor DNA Diagnostics Consumption Value Market Share by Application (2019-2030)
    Figure 38. Europe Circulating Tumor DNA Diagnostics Consumption Value Market Share by Country (2019-2030)
    Figure 39. Germany Circulating Tumor DNA Diagnostics Consumption Value (2019-2030) & (USD Million)
    Figure 40. France Circulating Tumor DNA Diagnostics Consumption Value (2019-2030) & (USD Million)
    Figure 41. United Kingdom Circulating Tumor DNA Diagnostics Consumption Value (2019-2030) & (USD Million)
    Figure 42. Russia Circulating Tumor DNA Diagnostics Consumption Value (2019-2030) & (USD Million)
    Figure 43. Italy Circulating Tumor DNA Diagnostics Consumption Value (2019-2030) & (USD Million)
    Figure 44. Asia-Pacific Circulating Tumor DNA Diagnostics Consumption Value Market Share by Type (2019-2030)
    Figure 45. Asia-Pacific Circulating Tumor DNA Diagnostics Consumption Value Market Share by Application (2019-2030)
    Figure 46. Asia-Pacific Circulating Tumor DNA Diagnostics Consumption Value Market Share by Region (2019-2030)
    Figure 47. China Circulating Tumor DNA Diagnostics Consumption Value (2019-2030) & (USD Million)
    Figure 48. Japan Circulating Tumor DNA Diagnostics Consumption Value (2019-2030) & (USD Million)
    Figure 49. South Korea Circulating Tumor DNA Diagnostics Consumption Value (2019-2030) & (USD Million)
    Figure 50. India Circulating Tumor DNA Diagnostics Consumption Value (2019-2030) & (USD Million)
    Figure 51. Southeast Asia Circulating Tumor DNA Diagnostics Consumption Value (2019-2030) & (USD Million)
    Figure 52. Australia Circulating Tumor DNA Diagnostics Consumption Value (2019-2030) & (USD Million)
    Figure 53. South America Circulating Tumor DNA Diagnostics Consumption Value Market Share by Type (2019-2030)
    Figure 54. South America Circulating Tumor DNA Diagnostics Consumption Value Market Share by Application (2019-2030)
    Figure 55. South America Circulating Tumor DNA Diagnostics Consumption Value Market Share by Country (2019-2030)
    Figure 56. Brazil Circulating Tumor DNA Diagnostics Consumption Value (2019-2030) & (USD Million)
    Figure 57. Argentina Circulating Tumor DNA Diagnostics Consumption Value (2019-2030) & (USD Million)
    Figure 58. Middle East and Africa Circulating Tumor DNA Diagnostics Consumption Value Market Share by Type (2019-2030)
    Figure 59. Middle East and Africa Circulating Tumor DNA Diagnostics Consumption Value Market Share by Application (2019-2030)
    Figure 60. Middle East and Africa Circulating Tumor DNA Diagnostics Consumption Value Market Share by Country (2019-2030)
    Figure 61. Turkey Circulating Tumor DNA Diagnostics Consumption Value (2019-2030) & (USD Million)
    Figure 62. Saudi Arabia Circulating Tumor DNA Diagnostics Consumption Value (2019-2030) & (USD Million)
    Figure 63. UAE Circulating Tumor DNA Diagnostics Consumption Value (2019-2030) & (USD Million)
    Figure 64. Circulating Tumor DNA Diagnostics Market Drivers
    Figure 65. Circulating Tumor DNA Diagnostics Market Restraints
    Figure 66. Circulating Tumor DNA Diagnostics Market Trends
    Figure 67. Porters Five Forces Analysis
    Figure 68. Manufacturing Cost Structure Analysis of Circulating Tumor DNA Diagnostics in 2023
    Figure 69. Manufacturing Process Analysis of Circulating Tumor DNA Diagnostics
    Figure 70. Circulating Tumor DNA Diagnostics Industrial Chain
    Figure 71. Methodology
    Figure 72. Research Process and Data Source

Research Methodology

Client Requirements

Review and analyze client requirements

Discussion of all the project requirements and queries

Flexibility Check

Project Feasibility Analysis

Finalizing tentative research programme

Structuring project proposal with scope, timeline, and costs

Analyzing Market Dynamics

Determination of key drivers, restraints, challenge, and opportunity

Identifies market needs and trends

Market Size Estimation & Forecast

Estimation of historical data based on secondary and primary data

Anticipating market recast by assigning weightage to market forces (drivers, restraints, opportunities)

Freezing historical and forecast market size estimations based on evolution, trends, outlook, and strategies

Consideration of geography, region-specific product/service demand for region segments

Consideration of product utilization rates, product demand outlook for segments by application or end-user.

Data Source

Secondary Source
Data collections from annual reports, presentations,associations, journals, analyst reports, paid database, press releases, blogs, newsletters,and GIR repositories.

Primary Source
Research discussion with manufacturers, distributors, suppliers, end user, industry experts to verify insights.

Validation and
triangulation of
secondary and primary source.

Collection of data

Cumulating and collating the essential qualitative and quantitative data

Generation of report in client requested format by research analysts

Reviews by expert analysts

Final quality check

Clarifying queries

Receiving feedback

Ensuring satisfaction

01 Identification of data

This step involves identification of several primary and secondary data research sources, including Global Info Research's internal data sources. The primary sources consist of in-depth discussions and interviews with policy makers, industry experts, and data evaluators, whereas secondary sources include a thorough study of market journals, press releases, annual reports, and government and non-government agencies websites.
02 Evaluation of Market Dynamic

This phase includes a detailed evaluation of several factors that are likely to affect the market dynamics. It involves a comprehensive assessment of major market pain points, drivers, and trends. It also comprises a detailed study of research plans and methodology.
03 Collection of Data

This process consists of gathering data, accessing proprietary databases, and reaching out to key industry participants that operate in the market across the value chain. It also involves studying several patterns in the historical data and comparing it with the current scenario.
04 Collaboration of Data

This stage involves the validation of data and arrival at actual statistics, and evolution of the market over the years. It entails the study and analyzes various segments and verticals of the market. An impact analysis is also performed to observe which factors will affect the market in the next few years.
05 Verification and Analysis

This is the final stage, which involves both quantity and quality checks. Although the process of data verification is an integral part of the research process, all data points and statistics and figures are re-checked to uphold their authenticity and validity.

Companies Mentioned

Grail, Inc.
Guardant Health, Inc.
Biodesix, Inc.
Exosome Diagnostics
Freenome Inc.
LungLife AI, Inc.
Inivata Ltd.
Personal Genome Diagnostics, Inc.
CellMax Life

Related Reports

Global Circulating Tumor DNA Diagnostics Market 2022 by Company, Regions, Type and Application, Forecast to 2028

Global Circulating Tumor DNA Diagnostics Market 2022 by Company, Regions, Type and Application, Forecast to 2028

date 12 Aug 2022

date Medical Care

The Circulating Tumor DNA Diagnostics market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations.

Global Circulating Tumor DNA Diagnostics Market 2023 by Company, Regions, Type and Application, Forecast to 2029

Global Circulating Tumor DNA Diagnostics Market 2023 by Company, Regions, Type and Application, Forecast to 2029

date 27 Feb 2023

date Medical Care

According to our (Global Info Research) latest study, the global Circulating Tumor DNA Diagnostics market size was valued at USD million in 2022 and is forecast to a readjusted size of USD million by 2029 with a CAGR of % during review period. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.

Global Circulating Tumor DNA Diagnostics Supply, Demand and Key Producers, 2023-2029

Global Circulating Tumor DNA Diagnostics Supply, Demand and Key Producers, 2023-2029

date 23 Mar 2023

date Medical Care

The global Circulating Tumor DNA Diagnostics market size is expected to reach $ million by 2029, rising at a market growth of % CAGR during the forecast period (2023-2029).

Product Tags

circulating tumor dna diagnostics

Organ Rejection Prophylaxis Treatment

Biologics Analytical Services

Purchase Options

Single User License

USD3480.00

Multi User License

USD5220.00

Corporate Users License

USD6960.00

Add To Cart

Buy Now

Popular Product Keywords

AI
semiconductor
electron
5G
artificial intelligence
Battery
new energy
We Provide Professional, Accurate Market Analysis to Help You Stay Ahead of Your Competition.

Speak to our analyst >>
Our Clients
What We Can Provide?

With better results and higher quality products,Our professional reports can achieve four things:
- Insight into the industry market information
- Analyze market development needs
- Prospects for future development
- Develop industry investment strategy
Digging deeper into global industry information and providing market strategies.

Contact Us >>